244 related articles for article (PubMed ID: 18823784)
1. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
[TBL] [Abstract][Full Text] [Related]
2. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Aug; 16(15):7347-57. PubMed ID: 18585046
[TBL] [Abstract][Full Text] [Related]
3. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives.
Hisamichi H; Naito R; Toyoshima A; Kawano N; Ichikawa A; Orita A; Orita M; Hamada N; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2005 Aug; 13(16):4936-51. PubMed ID: 15990316
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2009 Jan; 17(1):284-94. PubMed ID: 19010686
[TBL] [Abstract][Full Text] [Related]
5. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
7. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
[TBL] [Abstract][Full Text] [Related]
8. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Zhao H; Caflisch A
Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
[TBL] [Abstract][Full Text] [Related]
9. Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
Singh R; Masuda ES; Payan DG
J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213
[No Abstract] [Full Text] [Related]
10. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
[TBL] [Abstract][Full Text] [Related]
11. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
[TBL] [Abstract][Full Text] [Related]
12. Divergent synthesis of kinase inhibitor derivatives, leading to discovery of selective Gck inhibitors.
Matsumaru T; Inai M; Ishigami K; Iwamatsu T; Maita H; Otsuguro S; Nomura T; Matsuda A; Ichikawa S; Sakaitani M; Shuto S; Maenaka K; Kan T
Bioorg Med Chem Lett; 2017 May; 27(10):2144-2147. PubMed ID: 28385506
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
14. Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol.
Kaur M; Kumari A; Bahia MS; Silakari O
J Mol Graph Model; 2013 Feb; 39():165-75. PubMed ID: 23280414
[TBL] [Abstract][Full Text] [Related]
15. A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.
Norman P
Expert Opin Ther Pat; 2009 Oct; 19(10):1469-72. PubMed ID: 19552507
[TBL] [Abstract][Full Text] [Related]
16. Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
Lovering F; Aevazelis C; Chang J; Dehnhardt C; Fitz L; Han S; Janz K; Lee J; Kaila N; McDonald J; Moore W; Moretto A; Papaioannou N; Richard D; Ryan MS; Wan ZK; Thorarensen A
ChemMedChem; 2016 Jan; 11(2):217-33. PubMed ID: 26381330
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
18. 4-Chlorotetrazolo[1,5-a]quinoxaline inhibits activation of Syk kinase to suppress mast cells in vitro and mast cell-mediated passive cutaneous anaphylaxis in mice.
Park KL; Ko NY; Lee JH; Kim DK; Kim HS; Kim AR; Her E; Kim B; Kim HS; Moon EY; Kim YM; Kim HR; Choi WS
Toxicol Appl Pharmacol; 2011 Dec; 257(2):235-41. PubMed ID: 21958720
[TBL] [Abstract][Full Text] [Related]
19. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
